## **Core Concept**
Antibiotic-associated pseudomembranous colitis, also known as *Clostridioides difficile* infection (CDI), is a condition caused by the overgrowth of *Clostridioides difficile* bacteria in the gut, often following the use of broad-spectrum antibiotics. This condition leads to inflammation of the colon, resulting in symptoms such as diarrhea, abdominal pain, and potentially life-threatening complications. The treatment involves discontinuing the offending antibiotic, if possible, and administering specific antimicrobial therapy against *C. difficile*.

## **Why the Correct Answer is Right**
The correct answer, **Fidaxomicin** or more commonly **Vancomycin**, is effective in treating *C. difficile* infections because it is a non-absorbable antibiotic that acts locally in the gut. **Vancomycin** is a glycopeptide antibiotic that inhibits cell wall synthesis in *C. difficile*, effectively reducing the bacterial load. It is specifically indicated for the treatment of CDI and works by directly targeting the bacteria in the gastrointestinal tract without being absorbed systemically, thereby minimizing side effects.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Not specified, but assuming it's a commonly used antibiotic, if it's not effective against *C. difficile*, it would not be the best choice. Many antibiotics are ineffective against *C. difficile* due to its resistance profile.
- **Option B:** Similarly, without specifics, if this option does not have targeted activity against *C. difficile*, it's not suitable. Some antibiotics might even exacerbate CDI by disrupting the normal gut flora further.
- **Option D:** Assuming another antibiotic, if it does not have proven efficacy against *C. difficile* or is not recommended for CDI treatment, it would be incorrect.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Vancomycin** (or **Fidaxomicin**) is the drug of choice for treating *C. difficile* infections. It's crucial to use antibiotics judiciously and consider the risk of CDI when prescribing broad-spectrum antibiotics. Recurrent CDI can be challenging to manage and may require a different treatment approach, including fecal microbiota transplantation in severe cases.

## **Correct Answer:** . Vancomycin